[{"orgOrder":0,"company":"Vincere Biosciences","sponsor":"Hanall Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vincere Biosciences Announces Strategic Investment From Daewoong Pharmaceutical and HanAll Biopharma to Foster Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Vincere Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincere Biosciences \/ HanAll Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Vincere Biosciences \/ HanAll Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Vincere Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE 2024
                          Not Confirmed
                          FNCE 2024
                          Not Confirmed

                          Details : The collaboration aims to develop small-molecule, first-in-class disease-modifying therapies by targeting the modulation of mitochondrial quality control mechanisms such as mitophagy for Parkinson's patients by leveraging Vincere's proprietary AI platfor...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 12, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Hanall Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank